REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 155 filers reported holding REVANCE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,913,000 | -11.0% | 98,129 | -25.5% | 0.00% | 0.0% |
| Q4 2021 | $2,149,000 | -37.2% | 131,661 | +7.2% | 0.00% | 0.0% |
| Q3 2021 | $3,423,000 | -22.9% | 122,860 | -17.9% | 0.00% | 0.0% |
| Q2 2021 | $4,437,000 | -67.9% | 149,684 | -69.3% | 0.00% | -80.0% |
| Q4 2020 | $13,814,000 | -12.9% | 487,436 | -22.8% | 0.01% | -28.6% |
| Q3 2020 | $15,869,000 | +1.5% | 631,215 | -1.4% | 0.01% | 0.0% |
| Q2 2020 | $15,627,000 | +78.4% | 639,861 | +8.1% | 0.01% | +40.0% |
| Q1 2020 | $8,759,000 | -9.1% | 591,763 | -0.3% | 0.01% | +25.0% |
| Q4 2019 | $9,635,000 | +56.8% | 593,664 | +25.6% | 0.00% | +100.0% |
| Q3 2019 | $6,145,000 | +21.4% | 472,646 | +21.1% | 0.00% | 0.0% |
| Q2 2019 | $5,062,000 | -14.1% | 390,328 | +4.4% | 0.00% | 0.0% |
| Q1 2019 | $5,893,000 | +29.7% | 373,904 | +65.7% | 0.00% | 0.0% |
| Q4 2018 | $4,543,000 | +141.3% | 225,708 | +197.9% | 0.00% | +100.0% |
| Q3 2018 | $1,883,000 | – | 75,756 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NovaQuest Capital Management, L.L.C. | 1,558,426 | $48,000,000 | 65.50% |
| Essex Woodlands Management, Inc. | 3,842,047 | $118,335,000 | 25.90% |
| Rhenman & Partners Asset Management AB | 203,181 | $6,258,000 | 0.77% |
| EAM Global Investors LLC | 44,898 | $1,383,000 | 0.72% |
| Fosun International Ltd | 319,313 | $9,835,000 | 0.62% |
| EAM Investors, LLC | 113,096 | $3,483,000 | 0.58% |
| ArrowMark Colorado Holdings LLC | 1,735,699 | $53,460,000 | 0.53% |
| Perceptive Advisors | 618,957 | $19,064,000 | 0.53% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 111,360 | $3,430,000 | 0.45% |
| Schonfeld Strategic Advisors LLC | 83,700 | $2,578,000 | 0.19% |